Thursday, April 10, 2014
at the University of Leicester have shown that a
recombinant properdin produced in collaboration with The Medicines Co. has markedly higher
antibacterial activity than the native protein.1 The researchers are
now working to improve the activity and homogeneity of recombinant properdin to treat a broad range of infections.
immunotherapy for infections
thinks that the recombinant properdin has potential as an active immunotherapy
to treat infections.
Lou, K.-J. SciBX 7(14); doi:10.1038/scibx.2014.390
Published online April 10, 2014
1. Ali, Y.M. et al. Proc. Natl. Acad. Sci. USA; published online March 24, 2014;
Contact: Wilhelm J. Schwaeble, University of Leicester, Leicester,
2. Higgins, J.M. et al. J. Immunol. 155,
AND INSTITUTIONS MENTIONED
The Medicines Co. (NASDAQ:MDCO),
University of Leicester, Leicester, U.K.
University of Massachusetts Medical School, Worcester, Mass.
Washington University in St. Louis School of Medicine, St. Louis, Mo.